Nyxoah (NYXH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Nyxoah stock (NYXH) is currently trading at $3.17. Nyxoah PS ratio (Price-to-Sales) is 24.47. Analyst consensus price target for NYXH is $10.72. WallStSmart rates NYXH as Sell.
- NYXH PE ratio analysis and historical PE chart
- NYXH PS ratio (Price-to-Sales) history and trend
- NYXH intrinsic value — DCF, Graham Number, EPV models
- NYXH stock price prediction 2025 2026 2027 2028 2029 2030
- NYXH fair value vs current price
- NYXH insider transactions and insider buying
- Is NYXH undervalued or overvalued?
- Nyxoah financial analysis — revenue, earnings, cash flow
- NYXH Piotroski F-Score and Altman Z-Score
- NYXH analyst price target and Smart Rating
Nyxoah
📊 No data available
Try selecting a different time range
Smart Analysis
Nyxoah (NYXH) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Nyxoah (NYXH) Key Strengths (1)
Revenue surging 55.80% year-over-year
Supporting Valuation Data
Nyxoah (NYXH) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 24.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Fairly priced relative to book value
Supporting Valuation Data
Nyxoah (NYXH) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 55.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (24.47), Price/Book (2.42) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -107.60%, Operating Margin at -1236.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -107.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 55.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NYXH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NYXH's Price-to-Sales ratio of 24.47x sits near its historical average of 27.72x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 25% below its historical high of 32.47x set in Mar 2026, and 0% above its historical low of 24.44x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~32.5x as trailing revenue scaled faster than the stock price.
Compare NYXH with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Nyxoah (NYXH) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Nyxoah is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 6M with 56% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 56% YoY, reaching 6M. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
Spending 193% of revenue (11M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -21M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Nyxoah maintain 56%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Nyxoah.
Bottom Line
Nyxoah is a high-conviction growth story with revenue accelerating at 56% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:27:50 AM
About Nyxoah(NYXH)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Nyxoah is a pioneering medical technology firm specializing in the treatment of obstructive sleep apnea (OSA) through its innovative Genio system, which employs a minimally invasive hypoglossal nerve stimulation technique. The company is dedicated to enhancing patient outcomes and quality of life for those affected by OSA, backed by a strong commitment to clinical validation and research excellence. Nyxoah's strategic emphasis on technology advancement, complemented by partnerships and extensive studies, not only positions it to address significant unmet needs in the sleep medicine market but also underscores its potential for sustainable growth and transformative contributions to the healthcare industry.